Imunofan alongside multimodal breast cancer treatment in Samara
Comparison in people · 2004
- What was studied
- 174 patients with breast cancer treated in Samara from 2001 to 2003, 92 with adjunctive Imunofan and 82 controls.
- Main finding
- Local postoperative complications · 20/92 (21.7%) with Imunofan versus 24/82 (29.3%) with standard care, calculated from the reported counts. The printed p<0.01 does not agree with a simple comparison of those counts.
Reported findings and study design
Reported findings
The author abstract reports 50 µg (1 mL of 0.005% solution) intramuscularly daily for five days, in three courses after radiotherapy, after mastectomy and between chemotherapy cycles two and three. Total reported exposure was 750 µg.
Population or model 174 patients with breast cancer treated in Samara from 2001 to 2003, 92 with adjunctive Imunofan and 82 controls.
Dose, route and schedule
The author abstract reports 50 µg (1 mL of 0.005% solution) intramuscularly daily for five days, in three courses after radiotherapy, after mastectomy and between chemotherapy cycles two and three. Total reported exposure was 750 µg.
Protocol source ↗ · Author abstract methods, Table 1 and the stage IIIA clinical results.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Local postoperative complications | 20/92 (21.7%) with Imunofan versus 24/82 (29.3%) with standard care, calculated from the reported counts. The printed p<0.01 does not agree with a simple comparison of those counts. | |
| Lymph drainage lasting over 10 days | 16/92 (17.4%) versus 19/82 (23.2%), calculated from the reported counts. | |
| Wound suppuration | 2/92 versus 2/82. The author abstract describes no clear overall difference in wound complications. | |
| Stage IIIA leukopenia during chemotherapy | 3/20 versus 6/19, reported in the stage-specific comparison. |
Randomization and blinded assessment were not reported. The author abstract gives inconsistent percentages, subgroup denominators and significance statements. Differences in treatment tolerance cannot establish tumor control or survival benefit.
Source for these results ↗ · Reviewed 2026-11-14
Study limitations and source details
Study limitations
- Randomization and blinded assessment were not reported. The author abstract gives inconsistent percentages, subgroup denominators and significance statements. Differences in treatment tolerance cannot establish tumor control or survival benefit.
Related publications may describe some of the same participants or experiments.
Source details
Original dissertation author abstract
Author abstract methods, Table 1 and the stage IIIA clinical results.
Sources checked
Added to the library
Citation
T. G. Zolotareva. Imunofan alongside multimodal breast cancer treatment in Samara Candidate dissertation author abstract, Samara State Medical University, defended in Ufa, 2004.